Clinical Insight: Engaging PWID in HCV Care

Volume 6, Issue 4.

People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication.

In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

In the Clinic: Identifying & Managing HCV Complications

Volume 6, Issue 2.

In this podcast Andrea Granados, MD describes the clinical impact of the early diagnosis of glucose abnormalities in people with CF, summarizes the limitations of alternative modalities for screening and diagnosing CFRD, and and identifies the current recommendations for the management of CFRD.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

START HCV: Part 2

Hep C (HCV) treatment is easier and more effective, than ever. Cure is almost always expected when treated—even current drug users—so learn how you can cure HCV and help prevent re-infection, liver damage, cancer and death. Take the post-test to claim your credit.

New Options for Patients with “Hard-To-Treat” Hepatitis C Infection

Volume 5, Issue 12.

In this podcast Dr. Ira Jacobson discusses New Options for Patients with “Hard-To-Treat” Hepatitis C Infection.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Using Real World Data to Individualize HCV Management

Volume 5, Issue 10.

In this podcast Dr. David Wyles discusses managing DAA failures with the newly approved treatment options for hepatitis C.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Using Real World Data to Individualize HCV Management

Volume 5, Issue 8.

In this podcast, Andrew J. Muir, MD from Duke University School of Medicine discusses the real-world data to support a sofosbuvir-ledipasvir treatment duration of 8 weeks versus 12 weeks, summarizes the current hepatitis C treatment options for patients with advanced kidney disease, and describes the risks and benefits of hepatitis C therapies in HIV-HCV coinfected patients.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Clinical Insights: HCV and Substance Use Disorder

Volume 5, Issue 6.

This podcast, Andrew H. Talal, MD, MPH and Richard Blondell, MD from the University at Buffalo discuss expanding HCV screening in persons with substance abuse disorders.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.